Urokinase receptor promotes ovarian cancer cell dissemination through its 84-95 sequence

Oncotarget

Volumn 5, Issue 12, 2014, Pages 4154-4169

  Bifulco, Katia ^a   Votta, Giuseppina ^a   Ingangi, Vincenzo ^a   Di Carluccio, Gioconda ^a   Rea, Domenica ^a   Losito, Simona ^b   Montuori, Nunzia ^c   Ragno, Pia ^d   Stoppelli, Maria Patrizia ^a   Arra, Claudio ^a   Carriero, Maria Vincenza ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF SALERNO   (Italy)

Author keywords

Cell invasion; Ovarian cancer; Urokinase receptor

Indexed keywords

MATRIGEL; UROKINASE RECEPTOR;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY DENSITY; CELL INVASION; CELL MIGRATION; CHO K1 CELL LINE; CONTROLLED STUDY; DISSEMINATED CANCER; EXTRACELLULAR MATRIX; FEMALE; HAMSTER; HUMAN; HUMAN CELL; MESOTHELIUM; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PERITONEAL CAVITY; PROTEIN DOMAIN; PROTEIN EXPRESSION; TUMOR VOLUME; ANIMAL; CELL MOTION; CELL PROLIFERATION; GENETIC TRANSFECTION; GENETICS; MOUSE; NUDE MOUSE; OVARY TUMOR; PROGNOSIS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; TRANSFECTION;

EID: 84905114242     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1930     Document Type: Article

References (52)

1. Leroy-Dudal J, Demeilliers C, Gallet O, Pauthe E, Dutoit S, Agniel R, Gauduchon P, Carreiras F. Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves alphav integrins and the participation of MMP2. Int J Cancer. 2005; 114: 531-43.
2. Doig T, Monaghan H. Sampling the omentum in ovarian neoplasia: When one block is enough. Int J Gynecol Cancer. 2006; 16: 36-40.
3. Tan D, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet. 2006; 7: 925-34.
4. Landen C, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008; 26: 995-1005.
5. Lund IK, Illemann M, Thurison T, Christensen IJ, Høyer-Hansen G. uPAR as Anti-Cancer Target: Evaluation of Biomarker Potential, Histological Localization, and Antibody-Based Therapy Current Drug Targets. 2011; 12: 1744-60.
6. Wang L, Madigan MC, Chen H, Liu F, Patterson KI, Beretov J, O'Brien PM, Li Y. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients. Gynecol Oncol. 2009; 114: 265-72.
7. Kenny HA, Leonhardt P, Ladanyi A, Yamada SD, Montag A, Im HK, Jagadeeswaran S, Shaw DE, Mazar AP, Lengyel E. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res. 2011; 17: 459-71.
8. Al-Hassan NN, Behzadian A, Caldwell R, Ivanova VS, Syed V, Motamed K, Said NA. Differential roles of uPAR in peritoneal ovarian carcinomatosis. Neoplasia. 2012; 14: 259-70.
9. Jacobsen B, Ploug M. The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibitio. Curr Med Chem. 2008; 15: 2559-73. Review
10. Sier CF, Nicoletti I, Santovito ML, Frandsen T, Aletti G, Ferrari A, Lissoni A, Giavazzi R, Blasi F, Sidenius N. Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice. Thromb Haemost. 2004; 91: 403-11.
11. Henic E, Borgfeldt C, Christensen IJ, Casslén B, Høyer-Hansen G. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res. 2008; 14: 5785-93.
12. Mazar AP. Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res. 2008; 14: 5649-55.
13. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 2003; 22: 205-22.
14. Carriero MV, Stoppelli MP. The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling. Curr Pharm Des. 2011; 17: 1944-61.
15. Carriero MV, Del Vecchio S, Franco P, Potena M, Botti G, Stoppelli MP, Salvatore M. Vitronectin binding to urokinase receptor in human breast cancer. Clin Cancer Res. 1997; 3: 1299-308.
16. Carriero MV, Del Vecchio S, Capozzoli M, Franco P, Fontana L, Zannetti A, Botti G, D'Aiuto G, Salvatore M, and Stoppelli MP. Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res. 1999; 59: 5307-14.
17. Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M, Blasi F. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci USA. 2002; 99: 1359-64.
18. Montuori N, Carriero MV, Salzano S, Rossi G, Ragno P. The cleavage of the urokinase receptor regulates its multiple functions. J Biol Chem. 2002; 277: 46932-9.
19. Gargiulo L, Longanesi-Cattani I, Bifulco K, Franco P, Raiola R, Campiglia P, Grieco P, Peluso G, Stoppelli MP, Carriero MV. Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide. J Biol Chem. 2005; 280: 25225-32.
20. de Paulis A, Montuori N, Prevete N, Fiorentino I, Rossi FW, Visconte V, Rossi G, Marone G, Ragno P. Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and-like 2. J Immunol. 2004; 173: 5739-48.
21. Blasi F, Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett. 2010; 584: 1923-30.
22. Smith HW, Marshall CJ. Regulation of cell signaling by uPAR. Nat Rev Mol Cell Biol. 2010; 11: 23-36.
23. Gorrasi A, Li Santi A, Amodio G, Alfano D, Remondelli P, Montuori N, Ragno P. The Urokinase Receptor Takes Control of Cell Migration by Recruiting Integrins and FPR1 on the Cell Surface. PLoS One. 2014; 9: e86352.
24. Huai Q, Mazar AP, Kuo A, Parry GC, Shaw DE, Callahan J, Li Y, Yuan C, Bian C, Chen L, Furie B, Furie, BC, Cines DB, and Huang M. Structure of human urokinase plasminogen activator in complex with its receptor. Science. 2006; 311: 656-9.
25. Barinka C, Parry G, Callahan J, Shaw DE, Kuo A, Bdeir K, Mazar A, and Lubkowski J. Structural basis of interaction between urokinase-type plasminogen activator and its receptor. J Mol Biol. 2006; 363: 482-95.
26. Xu X, Gårdsvoll H, Yuan C, Lin L, Ploug M, Huang M. Crystal structure of the urokinase receptor in a ligand-free form. J Mol Biol. 2012; 416: 629-41.
27. Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 1997; 16: 7279-86.
28. Høyer-Hansen G, Rønne E, Solberg H, Behrendt N, Ploug M, Lund LR, Ellis V, DanøK. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem. 1992; 267: 18224-29.
29. Bifulco K, Longanesi-Cattani I, Gala M, DI Carluccio G, Masucci MT, Pavone V, Lista L, Arra C, Stoppelli MP, Carriero MV. The soluble form of urokinase receptor promotes angiogenesis through its Ser88-Arg-Ser-Arg-Tyr92 chemotactic sequence. J Thromb Haemost. 2010; 8: 2789-99.
30. Bifulco K, Longanesi-Cattani I, Franco P, Pavone V, Mugione P, Di Carluccio G, Masucci MT, Arra C, Pirozzi G, Stoppelli MP, Carriero MV. Single amino acid substitutions in the chemotactic sequence of urokinase receptor modulate cell migration and invasion. PLoS One. 2012; 7: e44806
31. Bifulco K, Longanesi-Cattani I, Gargiulo L, Maglio O, Cataldi M, De Rosa M, Stoppelli MP, Pavone V, Carriero MV. An urokinase receptor antagonist that inhibits cell migration by blocking the formyl peptide receptor. FEBS Lett. 2008; 582: 1141-6.
32. Carriero MV, Longanesi-Cattani I, Bifulco K, Maglio O, Lista L, Barbieri A, Votta G, Masucci MT, Arra C, Franco R, De Rosa M, Stoppelli MP, Pavone V. Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis. Mol Cancer Ther. 2009; 8: 2708-17.
33. Bifulco K, Longanesi-Cattani I, Liguori E, Arra C, Rea D, Masucci MT, De Rosa M, Pavone V, Stoppelli MP, Carriero MV. A urokinase receptor-derived peptide inhibiting VEGF-dependent directional migration and vascular sprouting. Mol Cancer Ther. 2013; 12: 1981-93.
34. Steinkamp MP, Winner KK, Davies S, Muller C, Zhang Y, Hoffman RM, Shirinifard A, Moses M, Jiang Y, Wilson BS. Ovarian tumor attachment, invasion, and vascularization reflect unique microenvironments in the peritoneum: insights from xenograft and mathematical models. Front Oncol. 2013; 3: 97.
35. Stylianou E, Jenner LA, Davies M, Coles GA, Williams JD. Isolation, culture and characterization of human peritoneal mesothelial cells. Kidney Int. 1990; 37: 1563-70.
36. Yang M, Chishima T, Wang X, Baranov E, Shimada H, Moossa AR, Hoffman RM. Multi-organ metastatic capability of Chinese hamster ovary cells revealed by green fluorescent protein (GFP) expression. Clin Exp Metastasis. 1999; 17: 417-22.
37. Naumov GN, Wilson SM, MacDonald IC, Schmidt EE, Morris VL, Groom AC, Hoffman RM, Chambers AF. Cellular expression of green fluorescent protein, coupled with high-resolution in vivo videomicroscopy, to monitor steps in tumor metastasis. J Cell Sci. 1999; 112: 1835-42.
38. Sandberg H, Lütkemeyer D, Kuprin S, Wrangel M, Almstedt A, Persson P, Ek V, Mikaelsson M. Mapping and partial characterization of proteases expressed by a CHO production cell line. Biotechnol Bioeng. 2006; 95: 961-71.
39. Franco P, Vocca I, Carriero MV, Alfano D, Cito L, Longanesi-Cattani I, Grieco P, Ossowski L, Stoppelli MP. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and (alpha)v(beta)5 integrin. J Cell Sci. 2006; 19: 3424-34
40. Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P, Nephew KP, Hales DB, Stack MS. Epithelial ovarian cancer experimental models. Oncogene. 2013 Aug 12.
41. Gårdsvoll H, Kjaergaard M, Jacobsen B, Kriegbaum MC, Huang M, Ploug M. Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor. J Biol Chem. 2011; 286: 43515-26.
42. Sidenius N, Blasi F. Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin. FEBS Lett. 2000; 470: 40-6.
43. Mazzieri R, D'Alessio S, Kenmoe RK, Ossowski L, Blasi F. An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration. Mol Biol Cell. 2006; 17: 367-78.
44. Wang Y, Liu J, Lin B, Wang C, Li Q, Liu S, Yan L, Zhang S, Iwamori M. Study on the Expression and Clinical Significances of Lewis y Antigen and Integrin α v, β 3 in Epithelial Ovarian Tumors. Int J Mol Sci. 2011; 12: 3409-21.
45. Sodek KL, Murphy KJ, Brown TJ, Ringuette MJ. Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev. 2012; 31: 397-414.
46. O'Halloran TV, Ahn R, Hankins P, Swindell E, Mazar AP. The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target. Theranostics. 2013; 3: 496-506.
47. Franco P, Carotenuto A, Marcozzi C, Votta G, Sarno C, Iaccarino I, Brancaccio D, De Vincenzo A, Novellino E, Grieco P, Stoppelli MP. Opposite modulation of cell migration by distinct subregions of urokinase connecting peptide. Chembiochem. 2013; 14: 882-9.
48. Rea VE, Lavecchia A, Di Giovanni C, Rossi FW, Gorrasi A, Pesapane A, de Paulis A, Ragno P, Montuori N. Discovery of new small molecules targeting the vitronectin-binding site of the urokinase receptor that block cancer cell invasion. Mol Cancer Ther. 2013; 12: 1402-16.
49. Arnaoutova I, Kleinman HK. In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract. Nat Protoc. 2010; 5: 628-35.
50. Topley N, Brown Z, Jörres A, Westwick J, Davies M, Coles GA, Williams JD. Human peritoneal mesothelial cells synthesize interleukin-8. Synergistic induction by interleukin-1 beta and tumor necrosis factor-alpha. Am J Pathol. 1993; 142: 1876-86.
51. Limame R, Wouters A, Pauwels B, Fransen E, Peeters M, Lardon F, De Wever O, Pauwels P. Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays. PLoS One. 2012; 7: e46536.
52. Sapra P, Kraft P, Pastorino F, Ribatti D, Dumble M, Mehlig M, Wang M, Ponzoni M, Greenberger LM, Horak ID. Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects. Angiogenesis. 2011; 14: 245-53.